Fulya EREN
(Bakırköy Sağlık Bilimleri Üniversitesi, Nöroloji Anabilim Dalı, Prof. Dr. Mazhar Osman Ruh Sağlığı ve Nöroloji Eğitim ve Araştırma Hastanesi, İstanbul, Türkiye)
Ayten CEYHAN DİRİCAN
(-)
Günay GÜL
(-)
Betül TEKİN
(-)
Dilek ATAKLI
(-)
Sevim BAYBAŞ
(-)
Yıl: 2021Cilt: 27Sayı: 1ISSN: 1300-7157Sayfa Aralığı: 47 - 51Türkçe

79 0
Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures
Objectives: Lacosamide (LCM) is a new generation amino acid drug that is used in patients with drug-resistant epilepsy, which increases the slow inactivation of voltage-dependent sodium channels. In this study, the short-term results of patients with drug-resistant epilepsy who received add-on LCM therapy were evaluated. Methods: Patients who were at least 16 years old and had focal onset seizures for a minimum period of 1 year were retrospectively assessed. Those who had uncontrolled seizures, despite the use of two appropriate antiepileptic drugs at an effective dose for at least six months, were included in the study. Forty-five eligible patients (11 females, 34 males) underwent further analysis. LCM therapy doses, change in seizure fre-quency, number of seizures before and after LCM therapy, and the effect of LCM add-on therapy on seizures were analyzed. Results: The mean age of the included 45 patients (11 females, 34 males) was 31.42 (16–56) years. Twenty-six of 45 (57.8%) patients under add-on therapy showed a decrease of 50% or more. It was observed that the seizure frequency decreased to a median of 2 (IQR: 0.5–5), which was statistically significant (p<0.001). The dose was not correlated with the seizure decrease ratio (p=0.216). The decrease in seizure frequency was similar in patients with LCM add-on treatment as the second or third drug, when compared with patients using LCM as the fourth or fifth drug (p=0.231).Conclusion: It was observed that LCM add-on therapy significantly decreased seizure frequency, similar to the current literature. On the con-trary, the dose effect or earlier add-on therapy did not show a significant effect on seizure frequency. LCM should be considered as a successful treatment option in patients with drug-resistant focal onset seizures.
DergiAraştırma MakalesiErişime Açık
  • 1. Hu Q, Zhang F, Teng W, Hao F, Zhang J, Yin M, et al. Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis. J Neurol 2018;265(1):1–11.
  • 2. Shneker BF, Fountain NB. Epilepsy. Dis Mon 2003;49(7):426–78.
  • 3. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002;58(8 Suppl 5):S2–8.
  • 4. Picot MC, Baldy-Moulinier M, Daurès JP, Dujols P, Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia 2008;49(7):1230–8.
  • 5. Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ 2014;348:g254.
  • 6. Baker MD, Abou-Khalil BW, Arain A, Tummala P, Azar NJ, Haas KF, et al. Lacosamide efficacy and tolerability in clinical practice - Post marketing analysis from a single dedicated epilepsy center. Clin Neurol Neurosurg 2018;171:179–83.
  • 7. Hoy SM. Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy. CNS Drugs 2018;32(5):473–84.
  • 8. Paquette V, Culley C, Greanya ED, Ensom MH. Lacosamide as adjunctive therapy in refractory epilepsy in adults: a systematic review. Seizure 2015;25:1–17.
  • 9. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, et al; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50(3):443- 53.
  • 10. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48(7):1308–17.
  • 11. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res 2001;47(1-2):17–25.
  • 12. Rosenow F, Kelemen A, Ben-Menachem E, McShea C, Isojarvi J, Doty P; SP774 study investigators. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand 2016;133(2):136–44.
  • 13. Neal A, D’Souza W, Hepworth G, Lawn N, Cook M, Nikpour A. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs. Epilepsy Behav 2018;80:25–32.
  • 14. Schultz L, Mahmoud SH. Is Therapeutic Drug Monitoring of Lacosamide Needed in Patients with Seizures and Epilepsy? Eur J Drug Metab Pharmacokinet 2020;45(3):315–49.
  • 15. Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav 2011;20(1):20–3.
  • 16. Villanueva V, Garcés M, López-Gomáriz E, Serratosa JM, González-Giráldez B, Parra J, et al. Early add-on lacosamide in a real-life setting: results of the REALLY study. Clin Drug Investig 2015;35(2):121–31.
  • 17. Villanueva V, Giráldez BG, Toledo M, De Haan GJ, Cumbo E, Gambardella A, et al. Lacosamide monotherapy in clinical practice: A retrospective chart review. Acta Neurol Scand 2018;138(3):186–94.
  • 18. Wechsler RT, Yates SL, Messenheimer J, Leroy R, Beller C, Doty P. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension. Epilepsy Res 2017;130:13–20

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.